On a roll, Vertex racks up impressive PhIII data for VX-659 combos in cystic fibrosis
Vertex $VRTX has come up with a stack of positive Phase III data points for their cystic fibrosis triple including the experimental VX-659. And its R&D group says they can ride these results all the way to an FDA approval.
Right now we’re just getting the primary endpoint readout, which is impressive. VX-659 is being credited with a 14% placebo-adjusted improvement from baseline in FEV1 for patients with one F508del mutation and one minimal function mutation, with a clear score on the p value (p<0.0001).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.